Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Utilizing TCR-Seq to Detect Tabelecleucel, an Allogeneic Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy, Post-Infusion

Fiona Ruiz, Tassja J. Spindler, Sumer Arthurs, Tiffany Jehng, Kate Widmann, Joseph M. Benoun, Yuanbin Ru, Aditi Mehta, Rajani Dinavahi, Jason A. Dubovsky, Cokey Nguyen

Blood (2022) 140 (Supplement 1): 4966–4967.

https://doi.org/10.1182/blood-2022-157709

Published: 2022

Journal Articles

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV + PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Wei Ye, Susan Prockop

Blood (2022) 140 (Supplement 1): 10374–10376.

https://doi.org/10.1182/blood-2022-157766

Published: 2022

Journal Articles

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

Susan Prockop, Laurence Gamelin, Rajani Dinavahi, Yan Sun, Weizhi Zhao, Faith Galderisi, Aditi Mehta

Blood (2021) 138 (Supplement 1): 887.

https://doi.org/10.1182/blood-2021-147226

Published: 2021